Other observational studies on patients with T2D have for hospitalisation for HF found a similar risk for GLP-1 RAs, a decreased risk for SGLT-2 inhibitors, and an increased risk for DPP-4 inhibitors when compared to a reference group [16, 40–44]. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.